Telmisartan combined with probucol effectively reduces urinary protein in patients with type 2 diabetes: A randomized double-blind placebo-controlled multicenter clinical study.

Abstract

BACKGROUND:

Persistent proteinuria is an important factor contributing to the progression of diabetic nephropathy. The present randomized double-blind placebo-controlled multicenter clinical study evaluated the efficacy and safety of telmisartan combined with the antioxidant probucol in reducing urinary protein levels in patients with type 2 diabetes (T2D).

METHODS:

Patients with T2D and 24-h proteinuria 0.5-3 g were enrolled in the study and randomly assigned to one of two groups: a telmisartan or a probucol + telmisartan group. Both groups were given telmisartan 80 mg q.d. for 48 weeks. The probucol + telmisartan group was given probucol 500 mg b.i.d. for the first 24 weeks, with the dosage then reduced to 250 mg b.i.d. for the remaining 24 weeks. The telmisartan group was given probucol placebo.

RESULTS:

In all, 160 patients were enrolled in the present study. The 24-h proteinuria levels were significantly reduced in the probucol + telmisartan compared with telmisartan group. For patients with baseline 24-h proteinuria levels <1.0 g, both treatments resulted in significant reductions in 24-h proteinuria levels after 48 weeks treatment. However, in patients with baseline 24-h proteinuria levels ≥1.0 g, 24-h proteinuria levels after 48 weeks treatment were only reduced in the probucol + telmisartan group. There was no significant difference between the two groups for either adverse cardiovascular or other events.

CONCLUSIONS:

In patients with diabetic nephropathy, probucol combined with telmisartan more effectively reduces urinary protein levels than telmisartan alone.

• Authors: Hanyu Zhu, Xiangmei Chen, Guangyan Cai, Ying Zheng, Moyan Liu, Wenhu Liu, Hebin Yao, Yaping Wang, Wenge Li, Hua Wu, Lide Lun, Jianrong Zhang, Xiaohong Guan, Shinan Yin, Xiaoming Zhuang, Jijun Li, Yanjun Liu, Chunhua Zhou
• Journal: Journal of diabetes (J Diabetes) Vol. 8 Issue 5 Pg. 677-85 (Sep 2016) ISSN: 1753-0407 [Electronic] Australia
• PMID: 26458146 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)
• Copyright: © 2015 The Authors. Journal of Diabetes published by Wiley Publishing Asia Pty Ltd and Ruijin Hospital, Shanghai Jiaotong University School of Medicine.

Chemical References

• Anticholesteremic Agents
• Benzimidazoles
• Benzoates
• Blood Glucose
• Glycated Hemoglobin A
• Lipoproteins, HDL
• Lipoproteins, LDL
• Cholesterol
• Probucol
• Telmisartan

Topics

• Aged
• Analysis of Variance
• Anticholesteremic Agents (adverse effects, therapeutic use)
• Benzimidazoles (adverse effects, therapeutic use)
• Benzoates (adverse effects, therapeutic use)
• Blood Glucose (metabolism)
• Cholesterol (blood)
• Diabetes Mellitus, Type 2 (blood, complications)
• Diabetic Nephropathies (etiology, prevention & control)
• Double-Blind Method
• Drug Therapy, Combination
• Female
• Glycated Hemoglobin (metabolism)
• Humans
• Hyperkalemia (chemically induced)
• Lipoproteins, HDL (blood)
• Lipoproteins, LDL (blood)
• Male
• Middle Aged
• Probucol (adverse effects, therapeutic use)
• Proteinuria (complications, prevention & control)
• Telmisartan
• Treatment Outcome